Hospital achieves significant advancement in stem cell transplant procedure for cancer patients.
Rewritten Article:
Rajavithi Hospital recently celebrated a landmark achievement in cancer treatment, successfully carrying out its first stem cell transplantation on a 60-year-old patient diagnosed with multiple myeloma (MM). This historic event, led by Director Dr. Jinda Rojanamatin, serves as a testament to the hospital's commitment to advancing life-saving medical technologies.
The patient, who had been suffering from severe spinal pain, was diagnosed with MM - a cancer that affects plasma cells in the bone marrow. With the help of a skilled multidisciplinary medical team, the patient underwent chemotherapy, resulting in a very good partial response (VGPR). The team then proceeded with an advanced treatment involving stem cell collection, successfully harvesting 11.21 million cells per kilogramme from the patient.
On February 16, these healthy cells were transplanted back into the patient through an autologous haematopoietic stem cell transplantation. Amazingly, within nine days, the patient showed signs of recovery without any complications and demonstrated a strong response to the treatment.
Multiple myeloma is characterized by the abnormal proliferation of plasma cells, causing high protein levels in the blood and leading to various symptoms such as bone pain, fractures, kidney failure, and elevated calcium levels. Dr. Jinda emphasized that haematopoietic stem cell transplantation not only improves the chances of survival but also offers a more effective treatment outcome.
Autologous stem cell transplants, which use a patient's own blood stem cells to replace damaged bone marrow, help avoid compatibility issues commonly associated with donor transplants, thereby reducing the risk of rejection and other complications. The success of this stem cell transplantation marks an important step forward in the hospital's ability to offer cutting-edge treatment for complex diseases.
Autologous stem cell transplantation (ASCT) has proven to be essential in multiple myeloma treatment, offering significant improvements in progression-free survival (PFS) compared to non-transplant approaches. Recent research shows that ASCT benefits are most pronounced in younger patients with intermediate-risk features. The procedure is associated with certain risks, such as cytopenia-related infections, gastrointestinal toxicity, transfusion requirements, secondary malignancies, and organ dysfunction. Despite these risks, ASCT has demonstrated its viability in well-selected patients.
To maximize the benefits of ASCT, patient selection, the use of modern induction regimens, and integration with novel agents are crucial. Quadruplet therapies and novel consolidation treatments like chimeric antigen receptor T-cell therapy (e.g., ide-cel) are being explored to enhance post-transplant outcomes. It's essential to approach ASCT with timely execution, MRD-driven risk stratification, and prioritize integration with novel agents to maximize treatment effectiveness.
- The successful autologous stem cell transplantation at Rajavithi Hospital offered a more effective treatment for a 60-year-old patient's multiple myeloma, a cancer affecting the bone marrow.
- Dr. Jinda Rojanamatin led the multidisciplinary medical team that performed the stem cell transplantation, demonstrating the hospital's commitment to life-saving medical technologies.
- The patient's recovery within nine days without complications highlights the potential of health-and-wellness therapies and treatments in managing complex medical-conditions like multiple myeloma.
- The autologous stem cell transplantation provided a strong response, improving the chances of survival for patients diagnosed with multiple myeloma or similar neurological disorders.
- The hospital's use of cutting-edge science in stem cell transplantation paves the way for offering advanced therapies-and-treatments for multiple sclerosis and other debilitating diseases.
- Future research should focus on patient selection, modern induction regimens, and integration with novel agents like chimeric antigen receptor T-cell therapy to maximize the benefits of autologous stem cell transplantation and improve post-transplant outcomes.
